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Abstract  
A discrete choice experiment was developed to investigate if girls aged 12-16 years make 
trade-offs between various aspects of human papillomavirus (HPV) vaccination, and to elicit 
the relative weight that girls’ place on these characteristics. Degree of protection against 
cervical cancer, protection duration, risk of side-effects, and age of vaccination, all proved to 
influence girls’ preferences for HPV vaccination. We found that girls were willing to trade-off 
38% protection against cervical cancer to obtain a life-time protection instead of a protection 
duration of 6 years, or 17% to obtain an HPV vaccination with a 1 per 750,000 instead of 1 
per 150,000 risk of serious side-effects. We conclude that girls indeed made a trade-off 
between degree of protection and other vaccine characteristics, and that uptake of HPV 
vaccination may change considerably if girls are supplied with new evidence-based 
information about the degree of protection against cervical cancer, the protection duration, 
and the risk of serious side-effects. 
 
Keywords: Cervical cancer; Human papillomavirus; Vaccination; Preferences; Discrete 
choice experiment 
 
Abbreviated title: Girls’ preferences for HPV vaccination 
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1. Introduction 
In countries with cytological screening programmes the mortality of cervical cancer has 
significantly decreased [1]. Since the discovery of human papillomavirus (HPV) as the cause 
of cervical cancer [2], new types of cervical cancer prevention, such as HPV screening and 
HPV vaccination, have been developed [3]. Currently HPV vaccines are available against 
HPVs 16 en 18, which have been estimated to cause 73-76% of cases of cervical cancer in 
Europe [4, 5]. HPV vaccination is useful for women who have not been previously infected 
with these HPV types since the protection against cancer for women with existing or previous 
infections of type 16 or 18 is low. By the end of 2008 fifteen countries of the European Union 
had decided to introduce HPV vaccination into their national immunisation schedule for 
adolescent girls, while another six have started the decision-making process with a 
recommendation favouring introduction [6].  
Attitude towards and uptake of the offered HPV vaccine may be influenced by its perceived 
advantages and drawbacks. Individuals may be willing to undergo an HPV vaccination 
despite several drawbacks (risk of side effects, injections needed) in order to maximize health 
benefit or, vice versa, they may accept a lower health benefit in order to avoid side-effects of 
vaccination. Research has shown that preferences (i.e. individual’s valuation) can have a 
major impact on the willingness to use health care services [7]. Several qualitative studies 
gave some insights into girls’ preferences for HPV vaccination [8-10]. However, quantitative 
studies investigating girls’ preferences for HPV vaccination and their willingness to trade-off 
between protection against cervical cancer and other characteristics of HPV vaccination are 
lacking.  
Therefore, this study investigates the preferences of girls aged 12-16 years for HPV 
vaccination through a discrete choice experiment (DCE), a quantitative approach that is 
increasingly used in health care [11, 12]. 
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2. Materials and Methods 
2.1 HPV vaccination 
In the Netherlands, a National Immunisation Programme (NIP) provides vaccinations against 
diphtheria, pertussis (whooping cough), tetanus, polio, type B Haemophilus influenzae, 
hepatitis B, mumps, measles, rubella (German measles) and meningococcosis C. In 2009, 
HPV vaccinations for 12-year-old girls (given as a series of three injections) were added to 
the NIP. To begin with, a catch-up programme was organised for girls aged 13 to 16 years. In 
the Netherlands, the HPV vaccine Cervarix is used, which protects against HPV-16 and HPV-
18. Parental consent for this vaccination is not needed as teenagers at the age of 12 years or 
older are officially allowed to decide for themselves whether they want to be vaccinated. All 
Dutch NIP vaccinations are offered free of charge. 
 
2.2 Discrete Choice Experiment 
DCEs, with their origin in marketing, are a novel approach to assess preferences for medical 
interventions. In DCEs it is assumed that a medical intervention, such as a vaccination 
programme, can be described by its characteristics (attributes; e.g. protection duration).[13] 
Those characteristics are further specified by variants of that characteristic (attribute levels; 
e.g. for protection duration: 6 years, 25 years, and lifetime). A second assumption is that  the 
individual’s preference for a medical intervention is determined by the levels of those 
attributes [13]. The relative importance of attributes and the trade-offs that respondents make 
between them can be assessed by offering a series of choices between two or more medical 
intervention alternatives with different combinations of attribute levels (see Table 1 for an 
example of a choice set) [14]. In comparison to other stated preference techniques, a DCE 
presents a reasonably straightforward task and one which more closely resembles a real-world 
decision, i.e. trading-off health and non-health outcomes [15]. 
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2.3 Attributes and attribute levels 
We selected the most relevant HPV vaccination attributes and their levels based on the 
literature, interviews with experts in the field of HPV vaccination (n=8), and focus groups 
data (n=4; 36 parents participated (34 female and 2 male), aged 33 to 53 years with at least 
one child in the age of 8 to 14 years. We did not include girls in the focus groups, because at 
that time it was expected that the target group for HPV vaccination would be 9-year old girls, 
who are under Dutch law not allowed to decide themselves about the vaccination uptake). In 
the focus groups we collected data on the attributes that individuals expected to be important 
or that had been important in their decision to participate in an HPV vaccination programme. 
Experts were asked to comment on a list of attributes, which were derived from a literature 
review, and to rank them in order of importance. Based on these data we selected the five 
most important attributes as identified by both groups: 1) degree of protection against cervical 
cancer; 2) protection duration; 3) serious side-effects (e.g. hospitalization); 4) mild side-
effects (e.g. nausea); and 5) age of vaccination. Attributes that were plausible and relevant 
both clinically and from a policy viewpoint were determined. A sufficiently wide range of 
levels was used to avoid respondents ignoring attributes because of too small differences in 
levels. The attributes and levels are presented in Table 2.  
 
2.4 Study design and questionnaire 
The combination of five attributes with three levels each resulted in 243 (3
5
) hypothetical 
HPV vaccination alternatives. Since it is not feasible to present a single individual with all 
these alternatives (i.e. full factorial design), we generated a sample of alternatives from all 
these 243 alternatives (i.e., we used a fractional factorial design) by means of a catalogue, 
which contains a library of orthogonal arrays [16]. Fifty-four HPV vaccination alternatives 
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proved sufficient to estimate all main effects and a number of two-way interactions between 
attributes in a regression analysis. In this fractional factorial design, attributes were 
independent of each other, thus guaranteeing orthogonality (i.e. the design was defined in 
such a way that the attributes could not represent the same facts), and attribute levels occurred 
with equal frequency, maintaining level balance [17]. Choice sets were designed using the 
discrete choice experiment software of Street and Burgess [18]. Our design, which contained 
54 choice sets, had an efficiency of 82% compared with an optimal choice design. This means 
that our design was a near optimal design that counterbalanced statistical reasons and practical 
reasons (a higher amount of choice sets will result in a more precise estimation of the 
coefficients, however as a consequence (much) more respondents are needed). Choice sets 
consisted of two HPV vaccination alternatives and a ‘no HPV vaccination’ option to allow 
respondents to ‘opt out’ (Table 1); HPV vaccination is a preventive medical intervention and, 
as in real life, respondents are not obliged to opt for HPV vaccination. Respondents were 
asked to consider all three options in a choice set as realistic alternatives and to choose the 
option that appealed most to them. Presenting a single individual with a large amount of 
choice sets is expected to result in a lower response rate and/or lower response reliability [19, 
20]. To avoid this, we used a blocked design [14], which resulted in dividing the 54 choice 
sets over six types of questionnaires containing nine choice sets each.  
Each questionnaire started with a detailed description of the attributes and their levels (the 
(complete) questionnaire is available from the authors on request). Pictures, graphs and 
pictograms were included to demonstrate percentages and rates. To assess the understanding 
of the attributes (protection levels against cervical cancer, levels of serious side effects, and 
levels of mild side-effects) the questionnaire contained a dominant choice set (rationality test). 
In this set one of two HPV vaccination alternatives was characterised by equal or logically 
preferable levels on all attributes.  
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The main part of each questionnaire comprised nine choice sets. Furthermore, the following 
data were collected: age at completing the questionnaire, level of education, religious 
affiliation, country of birth, parents’ countries of birth, history of childhood vaccinations, and 
of vaccinations against HPV. To check the convergent validity of the DCE, respondents were 
asked to rank the five attributes of HPV vaccination from most important to least important. 
The questionnaire was pilot tested to check for any problems in interpretation and face 
validity (n=16). 
 
2.5 Study sample 
A representative sample of 359 girls aged 12 to 16 years were randomly approached at 30 
classes from four secondary schools and cities located in the north-east (rural area) and west 
part (urban area) of the Netherlands. This age range was chosen based on current Dutch 
policy guideline. Calculation of optimal sample sizes for estimating non-linear discrete choice 
models from DCE data is complicated as it depends on the true values of the unknown 
parameters estimated in the choice models [21]. Lancsar and Louviere [21] mentioned that 
one rarely requires more than 20 respondents per parameter to estimate reliable models; our 
DCE contained eight parameters in the main effects model (see Equation 1), which meant that 
we had to include at least 160 respondents. Taking into account a suboptimal response rate, 
and some two-way interactions between attributes, we aimed at having at least 300 
questionnaires completed.  
 
2.6 Procedure 
Questionnaires were completed in the classroom or auditorium in the presence of a researcher 
or assistant. First, general information was given about HPV, cervical cancer, the causal link 
between them, HPV vaccinations, cervical cancer screening and the NIP (± 5 minutes). This 
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was followed by an explanation of DCE questions (± 5 minutes). Subsequently, respondents 
completed the questionnaire on paper (± 20-30 minutes). The whole procedure lasted at most 
45 minutes. Beforehand parents had received an information letter covering the purpose, 
voluntariness and anonymity of the study and an opt-out form. Approval for the study was 
obtained from the Medical Ethics Committee, Erasmus MC, University Medical Centre 
Rotterdam.  
 
2.7 Statistical analyses 
The DCE was analysed by taking each choice among the three options (two HPV vaccination 
alternatives, and a ‘no HPV vaccination’ alternative) as an observation, i.e. two ‘no’ and one 
‘yes’. The observations were analysed by a mixed logit regression model to take 
heterogeneity as well as correlation between the choice task completed by each individual into 
account [14]. After testing for linear continuous effects of one or more attributes, the 
following utility model was estimated:  
 
V = β0 + β1EFFECTIVENESS + β2DURATION_25Y + β3DURATION_LIFETIME + 
β4SERIOUS_1/150,000 + β5SERIOUS_1/30,000  + β6MILD + β7AGE_12Y + β8AGE_14Y 
                                                                                                                                (Eq. 1) 
 
V is the observable relative utility that is composed of the preference scores for the individual 
β-coefficients of the model. β0 is a constant reflecting respondents’ preference for receiving 
HPV vaccination relative to ‘no HPV vaccination’. β1-β8 are coefficients of the attributes 
indicating the relative weight individuals place on a certain attribute(level). The statistical 
significance of a coefficient (p-value ≤0.05) indicates that individuals differentiated between 
one attribute (or attribute level) and another in making stated choices. A priori, we expected 
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all attributes to be statistically significant. The sign of a coefficient reflects whether the 
attribute has a positive or negative effect on preference score. We expected that only the 
attribute ‘mild’ and the estimated attribute levels of ‘serious side-effects’ would have a 
negative effect (i.e., a negative sign). 
The value of each coefficient represents the importance respondents assign to an 
attribute(level). However, different attributes utilise different units of measurement. For 
example, the coefficient for ‘protection against cervical cancer’ represents the importance per 
absolute 10% protection rate. When looking at an HPV vaccination that generates a 70% 
protection rate, the coefficient should be multiplied seven times (7 * coefficient of ‘protection 
against cervical cancer’ of 10% = coefficient of ‘protection against cervical cancer’ of 70%).  
To explore the impact of respondents who failed the rationality test, sensitivity analyses were 
conducted by excluding such individuals from the sample and rerunning the analysis.[22, 23] 
Also, two-way interactions were added to the main effects model to test which two-way 
interactions were significant and improved the fit of the model. 
To investigate the willingness of girls to trade-off protection against cervical cancer to 
achieve an improvement in one level of the other HPV vaccination attributes, we calculated 
the ratios between the coefficients of the attributes with protection against cervical cancer as 
the denominator. For example, -β6/β1 indicates how much protection against cervical cancer 
girls were willing to forego to get an HPV vaccination programme that had a five percent 
lower risk in mild side-effects. 
Finally, choice probabilities were also calculated to provide a way to convey DCE results to 
decision makers that is more easily understandable. The probability that an individual says 
“yes” to an HPV vaccination programme is equal to: 
 
 P = 1 / (1+e
-V
) 
                                                                                                                              (Eq. 2) 
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where V is defined as in Equation 1. We calculated the choice probability (i.e. the mean 
uptake) for the base case. The base case used in this study represents an HPV vaccination 
programme at the age of 12 years, a 1/30 risk of mild side-effects, a 1/150,000 risk of serious 
side-effects; a protection duration of 6 years, and a 70% protection against cervical cancer. 
We presented these results in a ‘tornado’ graph [17] to illustrate the marginal effect of varying 
one attribute level at a time from the base case, holding all other attributes constant. This base 
was chosen to correspond i) with an HPV vaccination programme that contained most 
plausible levels based on literature, and ii) with the Dutch situation (HPV vaccination 
programme at the age of 12 years). The graph shows how each attribute systematically affects 
choices relative to the base case. Noteworthy, in the calculation of the mean uptake we took 
all heterogeneity into account as the mean uptake is not just equal to the uptake of someone 
with average coefficient values. Additionally, we calculated the minimum acceptable efficacy 
and maximum acceptable risk of mild side-effects, in which the base case HPV vaccination 
programme is preferred over no HPV vaccination (i.e. relative utility composed of the 
preference scores for the individual β-coefficients and standard deviations of the model is 
higher than zero). 
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3. Results 
 
3.1 Respondents 
The response rate was 312/359 (87%). The respondents had a mean age of 13.3 years 
(SD=1.0). Of all respondents, 58% had at least one dose of HPV-vaccine, 62% had a higher 
secondary educational level, and 38% considered themselves to be religious (Table 3). Results 
of direct ranking showed that the protection against cervical cancer, the protection duration, 
and the risk of serious side-effects of HPV vaccination were considered the most important 
attributes of an HPV vaccination programme (Figure 1). 
 
3.2 DCE results  
The ‘no HPV vaccination’ option was chosen in 21.4% of the choice sets. Twenty-one out of 
312 girls (6.7%) always chose the ‘no HPV vaccination’ option. All five vaccination 
characteristics proved to influence girls’ preferences for HPV vaccination (p<0.05; Table 4). 
The positive or negative directions of the coefficients of the characteristics were consistent 
with our a priori hypotheses and showed, therefore, theoretical validity. The positive sign 
given to the coefficients ‘degree of protection against cervical cancer’ and ‘protection 
duration’ indicated that respondents preferred an HPV vaccination generating a higher degree 
of protection and a longer protection duration over an HPV vaccination that generates a lower 
degree of protection and a shorter protection duration. The negative signs for ‘side-effects’ 
indicate that girls preferred an HPV vaccination programme with low serious and low mild 
side-effects. The non-significant coefficient of the characteristic level ‘vaccination at age 14 
years’ indicated that respondents did not significantly prefer this age of vaccination over a 
vaccination at age 9 years. However, respondents significantly preferred vaccination at age 12 
years over vaccination at age 9 years. Most estimated standard deviations were significant, 
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which indicated preference heterogeneity among girls for several characteristics of HPV 
vaccination.  
The results of the sensitivity analyses indicated that i) excluding respondents who ‘failed’ the 
rationality test (2.6% of the respondents) had no relevant impact on the size or relative 
importance of the attributes, and ii) none of the two-way interactions were significant and 
improved the fit of the model (data not shown).  
Comparing our DCE results with the results of the direct ranking in our questionnaire, both 
preference methods showed that protection against cervical cancer, protection duration, and 
risk of serious side-effects of HPV vaccination were considered the most important attributes 
of an HPV vaccination programme. These results support convergent validity of the DCE 
results.  
 
3.3 Trade-offs 
Based on the expressed preferences, girls showed their willingness to trade-off protection 
against cervical cancer to achieve an improvement in one level of the other HPV vaccination 
attributes (Table 5). On average, girls were willing to trade-off 38% protection against 
cervical cancer to obtain an HPV vaccination programme with a life-time protection duration 
instead of a protection duration of 6 years. Girls were willing to trade-off 17% protection 
against cervical cancer to obtain a vaccination with a risk of serious side effects of 1/750,000 
instead of 1/150,000, 9% protection against cervical cancer to get an HPV vaccination that 
had a five percent lower risk in mild side-effects, and 7% protection against cervical cancer to 
get an HPV vaccination at age 12 years instead of age 9 years. Considering the relative trade-
off between the risk of mild and serious side effects, girls were willing to accept a 9.7% (7.1% 
to 13.2%) increased risk of mild side effects if the risk of serious side effects decreased from 
1/150,000 to 1/750,000.  
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3.4 Expected uptake of HPV-vaccination 
We found an expected uptake of the base case HPV vaccination programme (70% protection 
against cervical cancer, at age 12 years, 1/30 risk of mild side-effects, 1/150,000 risk of 
serious side-effects, and protection duration of 6 years) of approximately 77% (CI: 74-80%). 
Especially an increased risk of serious side-effects from 1/150,000 to 1/30,000, a life-time 
protection instead of a protection duration of 6 years, or a decrease in protection against 
cervical cancer from 70% to 50% had a relatively large impact on the average expected 
uptake (a decrease of 14.6%, an increase of 12.0%, and a decrease of 7.3%, respectively) 
(Figure 2). Assuming an HPV vaccination at age 12 years, a 1/30 risk of mild side-effects, a 
1/150,000 risk of serious side-effects, and a protection duration of 6 years, the minimum 
efficiency of this HPV vaccination should be 15% to be preferred over no vaccination. Or 
assuming an HPV vaccination at age 12 years, a 1/150,000 risk of serious side-effects, a 
protection duration of 6 years, and a 70% protection rate against cervical cancer, the 
maximum risk for mild side effects should be 34% to be preferred over no vaccination.  
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4. Discussion 
The present study shows that girls made a trade-off between vaccine characteristics. Degree 
of protection against cervical cancer, duration of protection, risk of serious side-effects (e.g. 
hospitalization), risk of mild side-effects (e.g. nausea), and age of vaccination, all proved to 
influence girls’ preferences for HPV vaccination. On average, girls were willing to forego 
protection against cervical cancer if the protection duration of HPV vaccination was longer, or 
if the risk of serious or mild side-effects of HPV vaccination was lower. An increase in 
protection duration, an increase in risk of serious side-effects, or a decrease in degree of 
protection against cervical cancer had a relatively large impact on the average expected 
uptake.  
There are no previous DCEs investigating how characteristics of HPV vaccination determine 
girls’ preferences for participation in HPV vaccination. However, Dahlström et al. [24] 
investigated the attitudes to HPV vaccination among parents of children aged 12-15 years. 
They found that beliefs about vaccine safety and efficacy were strong correlates of 
willingness to vaccinate. Dempsey et al. [25], who investigated the reasons why mothers do or 
do not have their adolescent daughters vaccinated against HPV, concluded that addressing 
safety concerns may be one of the most useful targets for future interventions to increase HPV 
vaccine utilisation. Brown et al. [26], who estimated how features of HPV vaccines affect 
mothers’ perceived benefit for daughters aged 13-17 years, showed that cervical cancer 
protection and duration of effectiveness were the most important attributes. All these results 
are in line with the findings of our study, which show that protection against cervical cancer, 
protection duration, and serious side-effects play an important role in girls’ choices for HPV 
vaccination. In a vaccination context, Hall et al. [27] used a DCE to study the introduction of 
varicella vaccination. They showed that immunisation rates would increase in case of a lower 
incidence of mild and severe side-effects, which is similar to our study results. 
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The possibility to estimate the willingness to forego protection against cervical cancer is an 
additional advantage of DCE. However, in our opinion this additional advantage is limited. In 
the context of willingness to pay (WTP), earlier studies showed that the WTP derived from a 
DCE changed if a wider cost range was chosen [28], or that the WTP derived from an open-
ended question differed from the WTP derived from a DCE [29]. This same phenomenon 
might be possible for the willingness to forego protection against cervical cancer derived from 
a DCE. Further research in this area is needed and, meanwhile, we recommend the 
interpretation of these absolute willingness values to forego protection against cervical cancer 
in a relative manner (i.e. ranking order).  
Our results showed that the expected uptake of the base case HPV vaccination programme 
was much higher (76%) than the attendance rate in the first HPV vaccination round in the 
Netherlands in 2009 (49%) [30]. This 49% is also relatively low compared to the Dutch 
National Immunisation Programme for protection against childhood infectious disease 
(>95%).[31] Possible clarifications are uncertainty about the degree of protection against 
cervical cancer, protection duration, and serious side-effects (all of which played the most 
important role in girls’ preferences for HPV vaccination). To date, follow-up data on HPV 
vaccinated young women are available for 7.3 years [32, 33]. 
The present study had several limitations. First, our sample contained a relatively large 
number of high educated respondents, which precludes generalisation of the findings to all 
girls. Second, we selected the most relevant attributes in our DCE using literature, interviews 
with experts in the field of HPV vaccination, and focus group data; however, this careful 
procedure does not guarantee that we included all attributes that are relevant to girls’ 
preferences for HPV vaccination. Third, we did not include genital warts protection as an 
attribute of HPV vaccination as we did not receive signals that genital warts protection would 
play a role in the decision about HPV vaccination uptake, and as the Dutch vaccination 
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programme offers only Cervarix, which provides no protection against HPV types causing 
warts. However, girls may well have a preference for HPV vaccines offering warts protection. 
Fourth, the inclusion of percentages and rates in our discrete choice experiment, especially the 
inclusions of small risk levels, might have caused difficulties with understanding the choice 
task. Finally, the current results should preferably be validated by comparing them with the 
actual behaviour of girls in an HPV vaccination programme. 
In conclusion, this study shows that girls made trade-offs between protection against cervical 
cancer and other characteristics of HPV vaccination. Especially the degree of protection 
against cervical cancer, protection duration, and risk of serious side-effects influenced HPV 
vaccination preferences. We conclude that, uptake of HPV vaccination may change 
considerably if girls are supplied with new evidence-based information about the degree of 
protection against cervical cancer, the protection duration, and the risk of serious side-effects.  
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Table 1: Example of choice set  
 
Attributes
Program A Program B No vaccination
Protection against cervical 
cancer
70% 90% 0%
Protection duration Lifetime 6 years n.a.
Serious side-effects 1:750,000 1:750,000 No risk
Mild side-effects 1:50 1:30 No risk
Age at vaccination 14 years 9 years n.a.
Which vaccination 
program do you prefer? □  A □ B     □ None
 
 
n.a. = not applicable 
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Table 2: Considered attributes and attribute levels for HPV vaccination 
 
Coefficient  Attribute name 
β1 EFFECTIVENESS
50%
70%
90%
Protection duration 
6 years (reference level)
25 years β2 DURATION_25Y
lifetime β3 DURATION_LIFETIME
Serious side effects
1/750,000
1/150,00 β4 SERIOUS_1/150,000
1/30,000 β5 SERIOUS_1/30,000
Mild side effects β6 MILD
1/50
1/30
1/10
Age of vaccination 
at age 9 years (reference level)
at age 12 years β7 AGE_12Y
at age 14 years β8 AGE_14Y
Attributes and levels 
Protection against cervical cancer 
Regression analysis
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Table 3: Respondent characteristics 
 
Mean (SD)
13.3 (1.0)
n (%)
Lower secondary education 38 (12.2)
Intermediate secondary education 81 (26.0)
Higher secondary education 193 (61.9)
191 (61.2)
104 (33.3)
11 (3.5)
4 (1.3)
The Netherlands 293 (93.9)
Other (UK, France, Poland, Albania, Mexico, Aruba, 
Afghanistan, Pakistan, China, India, Iraq, Kazakhstan, 
Philippines
15 (4.9)
Both parents in the Netherlands 256 (82.1)
One parent outside the Netherlands 23 (7.4)
Both parents outside the Netherlands 26 (8.3)
Yes 181 (58.0)
Yes 259 (83.0)
No 5 (1.6)
Unknown 47 (15.1)
     Christian (incl. Catholic, Protestant)
     Moslim
Vaccinated against childhood diseases
Religion
     None
     Other 
Country of birth
HPV vaccinated
Country of birth of parents
Age (years)
Characteristics 
Educational level
Respondents                       
(n=312)
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Table 4: Girls’ preferences for HPV vaccination 
 
Coefficient Mixed logit
(95% CI)
Mean -0.28 (-0.92 to 0.36)
S.D. 3.60 *** (3.03 to 4.17)
Mean 0.64 *** (0.55 to 0.72)
S.D. 0.36 *** (0.30 to 0.42)
Protection duration 6 years (omitted) Mean -1.41 *** (-1.70 to -1.12)
S.D. 0.88 *** (0.87 to 0.90)
Protection duration 25 years Mean 0.20 *** (0.08 to 0.33)
S.D. 0.07 (-0.22 to 0.35)
Protection duration lifetime Mean 1.20 *** (1.03 to 1.37)
S.D. 0.88 *** (0.71 to 1.05)
1/750,000 risk on serious side effects (omitted) Mean 2.15 *** (1.89 to 2.40)
S.D. 0.80 *** (0.78 to 0.83)
1/150,000 risk on serious side effects Mean -0.55 *** (-0.68 to -0.43)
S.D. 0.18 * (0.04 to 0.40)
1/30,000 risk on serious side effects Mean -1.60 *** (-1.78 to -1.42)
S.D. 0.78 *** (0.56 to 1.01)
Mild side effects (per 5%) Mean -0.57 *** (-0.71 to -0.44)
S.D. 0.50 *** (0.30 to 0.71)
Vaccination at age 9 years (omitted) Mean -0.24 *** (-0.37 to -0.11)
S.D. 0.34 *** (0.32 to 0.35)
Vaccination at age 12 years Mean 0.21 *** (0.09 to 0.33)
S.D. 0.04 (-0.36 to 0.27)
Vaccination at age 14 years Mean 0.03 (-0.08 to 0.14)
S.D. 0.34 *** (0.18 to 0.49)
Number of responses
Number of respondents
Log-likelihood
Attributes
8,424
312
Value
Notes:  (1) Effects coded variables used for protection duration, serious side effects, and age at vaccination; 
(2) Normal distribution for random coefficients used on all attributes; (3) The value of the omitted term 
equals the negative sum of the coefficients of the included attributes; (4) *** denotes p<.01, ** p<.05, 
*p<0.10 for statistical significance; (5)  S.D. = standard deviation
Protection against cervical cancer (per 10%)
Constant (vaccination)
-1,735.60
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Table 5: Girls’ trade-offs between risk reduction and different aspects of a vaccination programme 
 
Interpretation note
Protection duration 37.8 (32.1 to 44.3) ….to get a vaccination with life-time protection instead of a protection duration of 6 years 
Serious side effects 17.4 (13.4 to 22.0) ….to get a vaccination with a risk of serious side effects of 1/750,000 instead of 1/150,000
Mild side effects 9.0 (6.9 to 11.2) ….to get a vaccination with a 5% lower risk of mild side-effects
Age of vaccination 6.6 (2.6 to 10.6) …to get a vaccination at age 12 years instead of age 9 years
were willing to forego 
protection against cervical 
cancer of…(%; CI)
Girls 
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Figure 1: Most important vaccination characteristic based on direct ranking (n=290 
respondents). 
Most important attribute
42.0%
28.3%
25.6%
2.4%
1.7%
Effectiveness
Duration
Serious side-effects
Mild side-effects
Age at vaccination
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Figure 2: Univariate marginal estimates for predicted probability of participation; highest and 
lowest values for attributes level changes versus base case 
5.1%
-7.3%
12.0%
2.4%
6.2%
-14.6%
0.7%
-5.6%
-2.3%
-2.7%
-50% -40% -30% -20% -10% 0% 10% 20%
90%
50%
Lifetime
25 yrs
1/750,000
1/30,000
1/50
1/10
14 yrs
9 yrs
Age at vaccination
Risk of mild side effects
Risk of serious 
side effects
Protection 
duration
Protection against 
cervical cancer
 
  
Note: The base case is an HPV vaccination at age 12 years, 1/30 risk of mild side-effects, 
1/150,000 risk of serious side-effects; protection duration of 6 years and 70% protection 
against cervical cancer. This base case is indicated as zero change in the probability of the x-
axis. 
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